In line with the clinical results, our established GBC organoids were largely heterogeneous and highly resistant to multiple targeted drugs approved by the FDA for tumour therapy, such as JAK‐STAT, protein kinase B, PKB (PI3K‐AKT) and PARP inhibitors. This evidence concerns the gene SOAT1 and neoplasm.